In patients over 75 years old, is ticagrelor (Brilinta) appropriate and what dosing and bleeding‑risk considerations apply?

Ticagrelor (Brilinta) in Patients Over 75 Years Old

Ticagrelor is appropriate and effective in patients over 75 years old with acute coronary syndrome (ACS), with no dose adjustment required, though bleeding risk must be carefully assessed. Unlike prasugrel, which is generally contraindicated in this age group, ticagrelor maintains its clinical benefit in elderly patients without age-related dosing modifications 1, 2.

Key Evidence for Use in Elderly Patients

The PLATO trial substudy specifically examined 2,878 patients ≥75 years and found that ticagrelor's clinical benefit over clopidogrel was consistent across age groups 3. The reduction in cardiovascular death, myocardial infarction, or stroke showed no significant age-by-treatment interaction (P=0.56), and importantly, there was no increase in major bleeding in elderly patients (HR 1.02,95% CI 0.82-1.27) 3.

Standard Dosing Regimen

For ACS patients over 75:

• Loading dose: 180 mg orally 1, 2, 4
• Maintenance dose: 90 mg twice daily for the first 12 months 1, 2, 4
• After 12 months: Consider reducing to 60 mg twice daily for extended therapy 4

No dose reduction is required based on age alone 4. This contrasts sharply with prasugrel, where patients ≥75 years face increased fatal and intracranial bleeding risk and the drug is generally not recommended except in high-risk situations 1, 2, 5.

Bleeding Risk Considerations

While ticagrelor does not show increased major bleeding compared to clopidogrel in elderly patients from the PLATO trial 3, a 2021 meta-analysis found a 20% increased risk of overall bleeding events (RR 1.20,95% CI 1.03-1.40) in patients ≥75 years, though major bleeding was not significantly different 6. This bleeding risk is substantially lower than the fatal and intracranial bleeding concerns associated with prasugrel in this age group 1, 2.

Specific Contraindications and Cautions:

• Absolute contraindications: History of intracranial hemorrhage, active pathological bleeding 2, 4
• Avoid in: Patients with prior ischemic stroke or TIA (uncertain risk of intracranial hemorrhage) 1, 2
• Monitor closely: Patients with propensity to bleed, concomitant anticoagulation, or on medications increasing bleeding risk 1, 2

Practical Management Approach

When to use ticagrelor over clopidogrel in elderly patients:

• ACS patients undergoing PCI or managed invasively 1, 7
• Patients at high ischemic risk (diabetes, prior MI, multivessel disease) 8
• When superior platelet inhibition is needed (e.g., stent thrombosis risk) 1, 9

When to consider clopidogrel instead:

• High bleeding risk patients (HAS-BLED score ≥3, prior bleeding events) 10
• Patients with prior stroke/TIA 1, 2
• Concerns about medication adherence with twice-daily dosing 1
• Patients experiencing dyspnea on ticagrelor (occurs in ~13% of elderly patients) 11

Common Pitfalls to Avoid

1. Do not reduce ticagrelor dose to 60 mg during the acute phase (first 12 months post-ACS). The 60 mg dose is only for extended therapy beyond 12 months or for chronic coronary syndrome 4.

2. Do not confuse with prasugrel dosing: Prasugrel requires dose reduction to 5 mg in patients ≥75 years (if used at all), but ticagrelor does not 1, 2, 10.

3. Maintain aspirin at 75-100 mg daily when using ticagrelor—higher aspirin doses reduce ticagrelor's efficacy 1, 2, 4.

4. Dyspnea is common but usually self-limiting: Occurs more frequently than with clopidogrel but rarely requires discontinuation 1, 2, 11, 12. If intolerable, switching to clopidogrel is reasonable 10.

Recent Evidence on Lower Dosing

The PLINY THE ELDER trial (2024) demonstrated that ticagrelor 60 mg twice daily provides non-inferior platelet inhibition compared to 90 mg in elderly patients (mean age 79.6 years) undergoing PCI 13. However, this was a pharmacodynamic study, not a clinical outcomes trial. Current guidelines do not support using 60 mg during the acute phase, but this may be considered for de-escalation after the initial high-risk period 10, 13.

Bottom Line Algorithm

For patients >75 years with ACS:

1. Assess bleeding risk first:

   • Prior intracranial hemorrhage or stroke/TIA → Use clopidogrel 1, 2
   • Active bleeding or very high bleeding risk → Use clopidogrel 10

2. If bleeding risk acceptable:

   • Give ticagrelor 180 mg loading dose, then 90 mg twice daily 1, 2, 4
   • Continue aspirin 75-100 mg daily 1, 2, 4
   • Maintain for 12 months 1, 2

3. After 12 months:

   • Consider reducing to 60 mg twice daily if continuing therapy 4
   • Reassess bleeding vs. ischemic risk regularly 10, 8

The most recent 2024 Canadian guidelines maintain ticagrelor as a Class I, Level B recommendation for ACS regardless of age, with individualization based on bleeding risk rather than age alone 10.